Printer Friendly

High hopes for dementia drug.

THE first drug that halts the progression of Alzheimer's disease has shown promising results in early clinical trials.

Aducanumab, an antibody, clears away sticky beta-amyloid protein deposits in the brain that are linked to dementia.

Scientists gave 165 patients monthly doses of aducanumab or a placebo. After 54 weeks, beta-amyloid levels had reduced in those given the drug. At higher doses, the drop was greater and associated with slower mental decline. Researchers, led by US firm Biogen, are recruiting patients for a larger trial, due to end in 2020.

Dr Eric Reiman, of Banner Alzheimer's Institute in Arizona, US, said aducanumab could be a "game changer for how we understand, treat and prevent the disease".

No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Mirror (London, England)
Date:Sep 1, 2016
Previous Article:TURTLE RECALL; Creature is returned home to aquarium after being nicked.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters